SEC Form 4 · accession 0001144204-15-067625
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John N Braca
Director
Period of report
Nov 19, 2015
Accepted (ET)
Nov 23, 2015 · 8:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Company Stock OptionF1 | $0.50 | Nov 19, 2015 | A | 42,500 | A | Nov 19, 2015 | Nov 19, 2025 | Common Stock | 42,500 | 42,500 | D |
Explanation of responses
- F1Such options were granted to Mr. Braca in lieu of cash compensation under the Company's independent director compensation plan and are immediately exercisable.